SAN DIEGO — With the Feb. 19 announcement by the US Food and Drug Administration that the drugs Celebrex and Bextra should remain on the market, data showing that higher doses of Celebrex are associated with increased cardiovascular risk may prove suddenly important to diagnostics companies with a CYP450 test capable of interrogating the 2C9 gene, which is involved in metabolizing both drugs.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.